These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1871 related items for PubMed ID: 31614149

  • 1. Nuclear factor I A promotes temozolomide resistance in glioblastoma via activation of nuclear factor κB pathway.
    Yu X, Wang M, Zuo J, Wahafu A, Mao P, Li R, Wu W, Xie W, Wang J.
    Life Sci; 2019 Nov 01; 236():116917. PubMed ID: 31614149
    [Abstract] [Full Text] [Related]

  • 2. IKBKE enhances TMZ-chemoresistance through upregulation of MGMT expression in glioblastoma.
    Guo G, Sun Y, Hong R, Xiong J, Lu Y, Liu Y, Lu J, Zhang Z, Guo C, Nan Y, Huang Q.
    Clin Transl Oncol; 2020 Aug 01; 22(8):1252-1262. PubMed ID: 31865606
    [Abstract] [Full Text] [Related]

  • 3. miR-126-3p sensitizes glioblastoma cells to temozolomide by inactivating Wnt/β-catenin signaling via targeting SOX2.
    Luo W, Yan D, Song Z, Zhu X, Liu X, Li X, Zhao S.
    Life Sci; 2019 Jun 01; 226():98-106. PubMed ID: 30980849
    [Abstract] [Full Text] [Related]

  • 4. The TNF receptor family member Fn14 is highly expressed in recurrent glioblastoma and in GBM patient-derived xenografts with acquired temozolomide resistance.
    Hersh DS, Harder BG, Roos A, Peng S, Heath JE, Legesse T, Kim AJ, Woodworth GF, Tran NL, Winkles JA.
    Neuro Oncol; 2018 Sep 03; 20(10):1321-1330. PubMed ID: 29897522
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Sulforaphane reverses chemo-resistance to temozolomide in glioblastoma cells by NF-κB-dependent pathway downregulating MGMT expression.
    Lan F, Yang Y, Han J, Wu Q, Yu H, Yue X.
    Int J Oncol; 2016 Feb 03; 48(2):559-68. PubMed ID: 26648123
    [Abstract] [Full Text] [Related]

  • 8. 20(S)-ginsenoside-Rg3 reverses temozolomide resistance and restrains epithelial-mesenchymal transition progression in glioblastoma.
    Chen Z, Wei X, Shen L, Zhu H, Zheng X.
    Cancer Sci; 2019 Jan 03; 110(1):389-400. PubMed ID: 30431207
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Regulation of temozolomide resistance in glioma cells via the RIP2/NF-κB/MGMT pathway.
    Hu YH, Jiao BH, Wang CY, Wu JL.
    CNS Neurosci Ther; 2021 May 03; 27(5):552-563. PubMed ID: 33460245
    [Abstract] [Full Text] [Related]

  • 12. Anticancer drug candidate CBL0137, which inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide-responsive and -resistant glioblastoma.
    Barone TA, Burkhart CA, Safina A, Haderski G, Gurova KV, Purmal AA, Gudkov AV, Plunkett RJ.
    Neuro Oncol; 2017 Feb 01; 19(2):186-196. PubMed ID: 27370399
    [Abstract] [Full Text] [Related]

  • 13. A novel tumor-promoting role for nuclear factor IA in glioblastomas is mediated through negative regulation of p53, p21, and PAI1.
    Lee JS, Xiao J, Patel P, Schade J, Wang J, Deneen B, Erdreich-Epstein A, Song HR.
    Neuro Oncol; 2014 Jan 01; 16(2):191-203. PubMed ID: 24305710
    [Abstract] [Full Text] [Related]

  • 14. Loss of PLK2 induces acquired resistance to temozolomide in GBM via activation of notch signaling.
    Alafate W, Xu D, Wu W, Xiang J, Ma X, Xie W, Bai X, Wang M, Wang J.
    J Exp Clin Cancer Res; 2020 Nov 11; 39(1):239. PubMed ID: 33176854
    [Abstract] [Full Text] [Related]

  • 15. Neuropilin-1 enhances temozolomide resistance in glioblastoma via the STAT1/p53/p21 axis.
    Huang P, Zhang L, Wang H, Dou C, Ju H, Yue P, Ren J.
    Neuropathology; 2024 Aug 11; 44(4):319-330. PubMed ID: 38448392
    [Abstract] [Full Text] [Related]

  • 16. PDIA3P1 promotes Temozolomide resistance in glioblastoma by inhibiting C/EBPβ degradation to facilitate proneural-to-mesenchymal transition.
    Gao Z, Xu J, Fan Y, Qi Y, Wang S, Zhao S, Guo X, Xue H, Deng L, Zhao R, Sun C, Zhang P, Li G.
    J Exp Clin Cancer Res; 2022 Jul 15; 41(1):223. PubMed ID: 35836243
    [Abstract] [Full Text] [Related]

  • 17. Down-regulation of MDR1 by Ad-DKK3 via Akt/NFκB pathways augments the anti-tumor effect of temozolomide in glioblastoma cells and a murine xenograft model.
    Fujihara T, Mizobuchi Y, Nakajima K, Kageji T, Matsuzaki K, Kitazato KT, Otsuka R, Hara K, Mure H, Okazaki T, Kuwayama K, Nagahiro S, Takagi Y.
    J Neurooncol; 2018 Sep 15; 139(2):323-332. PubMed ID: 29779087
    [Abstract] [Full Text] [Related]

  • 18. Exosomal transfer of miR‑25‑3p promotes the proliferation and temozolomide resistance of glioblastoma cells by targeting FBXW7.
    Wang J, Li T, Wang B.
    Int J Oncol; 2021 Aug 15; 59(2):. PubMed ID: 34278448
    [Abstract] [Full Text] [Related]

  • 19. MALAT1 is a prognostic factor in glioblastoma multiforme and induces chemoresistance to temozolomide through suppressing miR-203 and promoting thymidylate synthase expression.
    Chen W, Xu XK, Li JL, Kong KK, Li H, Chen C, He J, Wang F, Li P, Ge XS, Li FC.
    Oncotarget; 2017 Apr 04; 8(14):22783-22799. PubMed ID: 28187000
    [Abstract] [Full Text] [Related]

  • 20. Unveiling the role of TAGLN2 in glioblastoma: From proneural-mesenchymal transition to Temozolomide resistance.
    Li Y, Wang X, Xu T, Xu F, Chen T, Li Z, Wang Y, Chen H, Ming J, Cai J, Jiang C, Meng X.
    Cancer Lett; 2024 Aug 28; 598():217107. PubMed ID: 38992489
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 94.